Literature DB >> 15202088

[Angiogenesis in human cerebral ischemia].

A Rosell-Novel1, J Montaner, J Alvarez-Sabín.   

Abstract

OBJECTIVE: We aimed to review current knowledge about angiogenesis processes following stroke and possible benefit of future therapeutic angiogenic-related treatments. DEVELOPMENT: Angiogenesis is a physiopathologic process where new vessels arise from pre-existing ones within different phases: sprouting and maturation. To modulate angiogenesis there is a balance between several promoters like VEGF, bFGF, MMPs, etc. but also with inhibitors or angiostatic molecules such as angiostatin, endostatin, etc. In human pathologies angiogenesis has a dual effect: useful in wound healing, tissue remodelling or ischemic heart disease but harmful in cancer, rheumatoid arthritis or atheroma plaque instability and rupture. Angiogenesis is involved in some cerebrovascular diseases. Following ischemic stroke there is an overexpression of several molecules related with this process, although its finality remains largely unknown.
CONCLUSION: Angiogenesis is activated after stroke modifying capillary network. To obtain advantages from angiogenesis, it will be essential to achieve the temporal profile of these molecules in humans, and to investigate if its effects are different in acute or chronic stroke phases. In the future, angiogenesis modulation could take part of a combined stroke therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15202088

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  4 in total

1.  Genetic variant of BDNF (Val66Met) polymorphism attenuates stroke-induced angiogenic responses by enhancing anti-angiogenic mediator CD36 expression.

Authors:  Luye Qin; Eunhee Kim; Rajiv Ratan; Francis S Lee; Sunghee Cho
Journal:  J Neurosci       Date:  2011-01-12       Impact factor: 6.167

Review 2.  Intracranial arterial stenoses: current viewpoints, novel approaches, and surgical perspectives.

Authors:  Nestor R Gonzalez; David S Liebeskind; Joshua R Dusick; Fernando Mayor; Jeffrey Saver
Journal:  Neurosurg Rev       Date:  2012-10-25       Impact factor: 3.042

Review 3.  CD36 as a therapeutic target for endothelial dysfunction in stroke.

Authors:  Sunghee Cho
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Hypoxic preconditioning stimulates angiogenesis in ischemic penumbra after acute cerebral infarction.

Authors:  Sijie Li; Yanbo Zhang; Guo Shao; Mingfeng Yang; Jingzhong Niu; Guowei Lv; Xunming Ji
Journal:  Neural Regen Res       Date:  2013-11-05       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.